Innovative drugs approved via priority review pathway
RecordSTO-R0YVQBK50Z-FQ437EEKJ7-V1NH17
China · 2024
Innovative drugs approved via priority review pathway in China was 17 in 2024 (NMPA).
New drug approvals in China: every year, the rank and how it is measured
- Publisher
- NMPA
- Authority tier
- T1 Official
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.
Checked: the figure 17is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17
Other formats: MLA, Chicago, BibTeX
- MLA
- National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024, https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17.
- Chicago
- National Medical Products Administration. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024. https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17.
- BibTeX
- @misc{nmpa2024innovativev1nh17, author = {{National Medical Products Administration}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17}, note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\_1080286.htm. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- National Medical Products Administration · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- Measures facilitate approval of 48 first-in-class innovative drugs
- Type
- Press release
- Published
- —
- Locator
- Measures facilitate approval of 48 first-in-class innovative drugs
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Permanent URL
- /stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17